Control Strategy Considerations for the Continuous Manufacturing of Low-dose Oral Solid Dosage Formulations.

Area of Science:

• Pharmaceutical Manufacturing
• Process Analytical Technology
• Chemical Engineering

Background:

• Continuous Manufacturing (CM) adoption for Oral Solid Dosages (OSD) is hindered by Process Analytical Technology (PAT) limitations in monitoring low-dose formulations.
• Traditional PAT methods like Near-infrared (NIR) and Raman spectroscopy lack the sensitivity for accurate process control of low-dose or fixed-dose products.

Purpose of the Study:

• To explore advanced control strategies and alternative manufacturing technologies for overcoming PAT limitations in CM of low-dose OSD.
• To highlight methods ensuring content uniformity and robust process control in pharmaceutical manufacturing.

Main Methods:

• Enhanced spectroscopic methods (Spatially resolved-NIRS, Light-induced fluorescence) for improved accuracy.
• Process data and models (Residence Time Distribution, Multivariate Statistical Process Control) as soft sensors.
• Hybrid PAT and process models, at-line/off-line monitoring, and alternative technologies like semi-Continuous Manufacturing (sCM) and Dry Coating Technology.

Main Results:

• Advanced spectroscopic and data-driven approaches enhance process monitoring accuracy and precision.
• Technologies like sCM, Dry Coating, Twin-Screw Hot Melt Extrusion (HME), and twin screw wet granulation inherently ensure high content uniformity.
• Successful CM of low-dose products is achievable through strategic integration of advanced methods and innovative platforms.

Conclusions:

• Combining advanced spectral and data approaches, modeling, and innovative platforms enables robust process controls for CM of low-dose OSD.
• These integrated strategies are being incorporated into commercial pharmaceutical manufacturing processes.
• Overcoming PAT sensitivity limitations is key to the successful implementation of Continuous Manufacturing for challenging pharmaceutical formulations.